The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.
Bibliographical noteFunding Information:
2Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; 3Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200240, China; 4Sun Yat-sen University Cancer Center, Guangzhou 510030, China; 5Center for Food and Drug Inspection of China Food and Drug Administration, 6Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; 7Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 8Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing 100071, China; 9Department of Oncology, Peking University International Hospital, Beijing 102206, China; 10Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310000, China; 11Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210008, China; 12Department of Chemotherapy, Jiangsu Cancer Hospital, Hangzhou 310000, China; 13Department of Oncology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou 310003, China; 14Department of Oncology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China; 15Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200092, China; 16Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China; 17Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China; 18Department of Respiratory Medicine, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing 400042, China; 19Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fujian 350001, China; 20Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 21Institute of Immunotherapy, Fujian Medical University, Fuzhou 350004, China; 22Department of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing 400030, China; 23Department of Internal Oncology, 301 General Hospital, Beijing 100853, China; 24Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou 510010, China; 25Cancer Center of Renmin Hospital, Wuhan University, Wuhan 430070, China; 26Department of Oncology, Hu Nan Provincial Tumor Hospital, Changsha 410006, China; 27Department of Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350011, China; 28Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330039, China; 29Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; 30Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; 31Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou 310006, China; 32Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China; 33Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China; 34Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710006, China; 35Department of Thoracic Surgery, Peking University People Hospital, Beijing 100044, China; 36Department of Oncology, Anhui Medical University, Hefei 230032, China; 37Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 100069, China; 38Beijing Gene+ Technology, Beijing 102208, China Contributions: (I) Conception and design: YL Wu; (II) Administrative support: YL Wu; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: YL Wu, H Sun; (V) Data analysis and interpretation: YL Wu, H Sun; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Yi-Long Wu. Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Email: email@example.com.
- Lung cancer